CJC-1295 and Finasteride Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Comes Up

Men pursuing hair retention with finasteride often explore peptide therapy for body composition, recovery, or anti-aging goals. CJC-1295 (modified GRF 1-29), a growth hormone-releasing hormone (GHRH) analog, ranks among the most commonly requested peptides in telehealth consultations. The question of whether these two agents conflict is practical, not theoretical.

Finasteride earned FDA approval in 1992 for benign prostatic hyperplasia (BPH) at 5 mg and in 1997 for male androgenetic alopecia (AGA) at 1 mg [1]. CJC-1295, by contrast, has no FDA approval. It is dispensed through compounding pharmacies under Section 503A and has been studied in only a handful of clinical trials [2]. This regulatory asymmetry matters because it means interaction data comes from mechanistic reasoning and case series rather than randomized controlled trials designed to test the combination.

A 2006 dose-escalation study (N=21) published in the Journal of Clinical Endocrinology & Metabolism confirmed that CJC-1295 with drug affinity complex (DAC) produced sustained GH and IGF-1 elevation for 6 to 14 days after a single subcutaneous injection [2]. That prolonged hormonal window is exactly what raises pharmacodynamic questions when layered on top of a drug that reshapes androgen conversion.

Pharmacokinetic Assessment: Separate Metabolic Highways

CJC-1295 and finasteride do not share metabolic machinery. This means one drug will not raise or lower blood levels of the other through enzyme competition.

CJC-1295 is a 29-amino-acid peptide. Like other peptides of its size, it undergoes proteolytic cleavage by tissue and plasma peptidases rather than oxidative metabolism in the liver [3]. It does not serve as a substrate, inhibitor, or inducer of cytochrome P450 enzymes. It has no known interaction with P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs).

Finasteride is metabolized primarily by CYP3A4, with a minor contribution from CYP3A5 [4]. Its bioavailability is approximately 80%, and it does not inhibit or induce major CYP isoforms at therapeutic concentrations. The FDA label for Proscar states that "no drug interactions of clinical importance have been identified" in formal interaction studies with propranolol, digoxin, warfarin, theophylline, and antipyrine [1].

Because CJC-1295 bypasses hepatic CYP metabolism entirely, there is no mechanistic basis for a pharmacokinetic interaction. Co-administration should not alter the area under the curve (AUC), peak concentration (Cmax), or half-life of either agent.

Pharmacodynamic Overlap: Where GH Meets Androgen Metabolism

The real clinical question is pharmacodynamic, not pharmacokinetic. GH and IGF-1 influence several pathways that intersect with androgen biology.

GH stimulates hepatic IGF-1 production. IGF-1 receptors are expressed on dermal papilla cells of hair follicles, where IGF-1 signaling promotes anagen (growth phase) entry and prolongs the hair cycle [5]. This effect is directionally favorable for someone using finasteride for hair retention. A 2012 study in the Journal of Investigative Dermatology demonstrated that IGF-1 signaling maintains hair follicle growth and delays catagen transition [5].

The more nuanced concern involves GH's influence on androgen metabolism. GH administration has been shown to increase the metabolic clearance rate of testosterone [6]. In some contexts, GH therapy modestly increases free testosterone by reducing sex hormone-binding globulin (SHBG) concentrations. A study of GH-deficient adults receiving replacement doses found that GH reduced SHBG by 15-20%, resulting in higher calculated free testosterone [6]. If free testosterone rises, more substrate becomes available for 5-alpha reductase, the enzyme finasteride inhibits.

Does this blunt finasteride's effect? Probably not to a clinically meaningful degree in most patients. Finasteride at 1 mg reduces scalp DHT by approximately 64% and serum DHT by about 70% [7]. That suppression is strong enough to accommodate modest shifts in testosterone availability. A patient whose free testosterone increases by 10-15% from GH-axis stimulation would still experience substantial DHT reduction on finasteride.

The scenario where this could matter is a patient who is already a partial responder to finasteride. If GH-driven increases in free testosterone push DHT production above the threshold that finasteride can suppress, the clinical benefit for hair retention could narrow. This is a theoretical concern that warrants monitoring, not a contraindication.

Insulin Sensitivity: A Shared Side Effect Worth Tracking

Both agents affect glucose homeostasis, though in opposite directions at certain doses.

GH is diabetogenic. It promotes lipolysis and antagonizes insulin signaling in skeletal muscle and adipose tissue. The Teichman et al. study of CJC-1295 reported dose-dependent GH elevations but did not observe clinically significant glucose changes during the short study period [2]. Longer-term use of GHRH analogs, however, carries the same insulin resistance risk as exogenous GH. A review in Endocrine Reviews noted that supraphysiologic GH levels consistently impair glucose tolerance [8].

Finasteride, for its part, does not directly affect insulin sensitivity. But a 2019 analysis published in the World Journal of Men's Health found that long-term finasteride use was associated with small improvements in metabolic markers in some populations, likely mediated through changes in androgen milieu [9]. The clinical significance of this is modest.

For the patient combining both agents, the practical instruction is straightforward: obtain a fasting glucose and hemoglobin A1c at baseline and at 12-week follow-up. If fasting glucose exceeds 100 mg/dL or A1c rises above 5.7%, the GH-stimulating component (CJC-1295) should be the first agent reassessed.

Monitoring Protocol for Concurrent Use

A structured lab panel removes guesswork from this combination. The following schedule reflects the pharmacology of both drugs.

Baseline (before starting the combination):

• IGF-1
• Total and free testosterone
• DHT
• Fasting glucose and HbA1c
• Complete metabolic panel (CMP)

Week 8-12:

• IGF-1 (target: upper quartile of age-adjusted normal, not above range)
• DHT (confirm continued suppression on finasteride)
• Fasting glucose

Every 6 months thereafter:

• IGF-1
• DHT (if hair loss is the indication for finasteride)
• Fasting glucose or HbA1c
• PSA for men over 40 (per AUA guidelines for patients on 5-alpha reductase inhibitors) [10]

The PSA check deserves specific attention. Finasteride reduces PSA by approximately 50% at steady state. Clinicians must double the measured PSA value to estimate the true reading. GH does not independently raise PSA, but any hormonal therapy that shifts the androgen axis justifies continued surveillance per the American Urological Association's 2018 position [10].

Finasteride Sexual Side Effects and GH Axis Considerations

Finasteride's most discussed adverse effects are sexual: reduced libido, erectile dysfunction, and decreased ejaculate volume occur in 1.3-3.7% of men in key trials [1]. These effects are attributed to DHT suppression in tissues where DHT mediates sexual function.

GH and IGF-1 play supportive roles in male sexual physiology. GH receptors are present in the corpus cavernosum, and IGF-1 promotes nitric oxide synthase expression in penile endothelial cells [11]. A 2009 study in the International Journal of Impotence Research reported that GH-deficient men had higher rates of erectile dysfunction, which improved with GH replacement [11].

This creates an interesting theoretical scenario: could CJC-1295-driven GH/IGF-1 elevation partially offset finasteride's sexual side effects? No trial has tested this directly. The mechanistic logic is plausible but unproven. Patients should not rely on CJC-1295 as a countermeasure for finasteride-related sexual dysfunction. If sexual side effects emerge, the evidence-based response is to reduce the finasteride dose to 0.5 mg or 0.25 mg daily, which maintains 50-60% of DHT suppression while reducing side effect burden [12].

Timing and Administration Practicalities

CJC-1295 (modified GRF 1-29, without DAC) is typically administered subcutaneously at 100-300 mcg per injection, one to three times daily, often combined with a GHRP such as ipamorelin. The version with DAC (drug affinity complex) extends the half-life and is dosed at 2 mg once or twice weekly [2].

Finasteride is taken orally, once daily, with no food restrictions.

There is no pharmacologic reason to separate administration times. GH release from CJC-1295 peaks 15-30 minutes post-injection and does not interfere with finasteride absorption or hepatic processing. Many clinicians instruct patients to inject CJC-1295 before bed to align with the natural nocturnal GH pulse. Finasteride can be taken at any consistent time.

Populations Requiring Extra Caution

Certain patient profiles warrant closer oversight when combining these agents.

Men over 50 with BPH: Finasteride at 5 mg (Proscar) is used for prostate volume reduction. GH promotes cellular proliferation broadly. While no study has linked GHRH analog use to prostate growth, the theoretical concern exists. The PCPT trial (N=18,882) showed that finasteride reduced overall prostate cancer incidence by 24.8% over 7 years but was associated with a small increase in high-grade tumors, a finding later attributed to detection bias [13]. Adding a GH secretagogue to this population demands informed consent and PSA monitoring every 6 months.

Pre-diabetic patients: As discussed, GH antagonizes insulin action. A patient with fasting glucose of 100-125 mg/dL who adds CJC-1295 could cross into diabetic range. Finasteride does not offset this risk. Metformin co-administration or CJC-1295 dose reduction are appropriate responses [8].

Patients with active malignancy or history of hormone-sensitive cancer: GH and IGF-1 are mitogenic. The Endocrine Society's 2011 guidelines on GH replacement in adults recommend against GH therapy in patients with active malignancy [14]. This extends to GH secretagogues like CJC-1295. Finasteride, conversely, has protective associations in prostate cancer prevention [13]. The combination is inappropriate in this population.

What the FDA Labels Say (and Do Not Say)

The finasteride label (Proscar/Propecia) does not mention CJC-1295, peptide secretagogues, or GH-releasing agents in its drug interaction section [1]. This is expected. Finasteride's formal interaction studies were conducted with commonly co-prescribed drugs in the BPH and cardiovascular populations.

CJC-1295 has no FDA label. The compound is referenced in FDA warning letters to compounding pharmacies and in the agency's broader statements about peptide regulation. The absence of a label means the absence of a formal interaction table, shifting the clinical responsibility to the prescribing provider.

No major drug interaction database (Lexicomp, Micromedex, Clinical Pharmacology) includes CJC-1295 entries. When a clinician queries "CJC-1295 + finasteride," the database returns no results. This is not evidence of safety. It is evidence of insufficient data. The interaction assessment must therefore rely on first-principles pharmacology, which, as outlined above, identifies low pharmacokinetic risk and manageable pharmacodynamic considerations.

Clinical Bottom Line

The CJC-1295 and finasteride combination carries no identified pharmacokinetic interaction and a low-severity pharmacodynamic overlap related to GH-mediated shifts in free testosterone and insulin sensitivity. Patients using both agents should have IGF-1, DHT, and fasting glucose checked at baseline and 8-12 weeks. Dose adjustment of either drug is not routinely needed, but partial finasteride responders with rising free testosterone may need DHT levels rechecked to confirm continued suppression. Men over 50 taking finasteride for BPH should maintain PSA surveillance every 6 months, with values doubled to account for finasteride's PSA-lowering effect [10].